

# blood

JOURNAL OF  
THE AMERICAN  
SOCIETY OF  
HEMATOLOGY

VOLUME 96  
NUMBER 3  
AUGUST 1, 2000


Review:  
*IG* translocation  
and B-cell  
malignancy

Review:  
erythropoietin  
and iron

CD4 $\zeta$ -modified  
T cells in AIDS

GM-CSF receptor-  
associated protein


$\alpha$ -Thalassemia  
and chromosomal  
positioning



RECEIVED  
UCF LIBRARY

AUG 07 2000

## Serials



*Blood*, Journal of The American Society of Hematology (ISSN 0006-4971), is published 25 times (in 2 volumes) per year by The American Society of Hematology (ASH), 1900 M Street, NW, Suite 200, Washington, DC 20036. Dates of issue are the 1st and the 15th of each month, except in November, when 3 issues are published. Printed in the United States of America. Periodicals postage paid at Washington, DC, and additional mailing offices.

**Postmaster:** Send changes of address to *Blood*, Journal of The American Society of Hematology, 1900 M Street, NW, Suite 200, Washington, DC 20036.

### Manuscript submissions

Consult the Author Guide printed in each issue of *Blood* (and posted on the web site at [www.bloodjournal.org](http://www.bloodjournal.org)) before submitting 3 hard copies of the manuscript, 1 diskette, and 3 complete sets of figures to:

Kenneth Kaushansky, MD  
Editor-in-Chief, *Blood*  
1900 M Street, NW, Suite 200  
Washington, DC 20036

### Author proofs

*Blood* will be copyedited by the *Blood* Production staff in the Washington, DC, Publishing Office. Authors should return their page proofs and all related material within 48 hours of receipt to the *Blood* Production Office, 1900 M Street, NW, Suite 200, Washington, DC 20036. Tel: 202-292-0027.

### 2000 subscription rates

**United States and possessions:** individual, \$532; institution, \$748. **All other countries:** individual, \$747; institution, \$897. There is no additional charge for surface delivery to any area outside the United States and possessions. For airmail delivery, add \$144 to your subscription price. *Blood* offers a reduced rate for students, interns, and residents who are in approved hematology or oncology programs: United States and possessions, \$244; all other countries, \$667. To qualify, supply your name, dates of study, and the signature of your academic advisor on institutional letterhead. Orders will be billed at the individual rate until proof of status is received. All subscriptions are accepted on a calendar-year basis.

**The price for single/back issues** is \$38. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. Back issues sold in conjunction with a subscription are prorated.

### Subscription information, claims, or changes of address

**Customer Service for Subscribers: 1-800-654-2452 (US & Canada); 1-407-345-4000 (outside US & Canada).** Correspondence regarding (nonmember) subscriptions or change of address should be addressed to *Blood* Journal Subscriptions (c/o W. B. Saunders), PO Box 628239, Orlando, FL 32862-8239. Checks should be made payable to *Blood* Subscriptions.

ASH Members should send their change-of-address information to the ASH Membership Department, 1900 M Street, NW, Suite 200, Washington, DC 20036.

All change-of-address notices should be sent at least 6 weeks prior to the date of issue, with both old and new addresses given.

### Internet

**Blood Home Page:** [www.bloodjournal.org](http://www.bloodjournal.org).

**ASH Home Page:** [www.hematology.org](http://www.hematology.org).

### Copyright

Copyright © 2000 by The American Society of Hematology. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means now or hereafter known, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the Publisher, The American Society of Hematology.

**Correspondence regarding permission to reprint** all or part of any article published in this journal should be addressed to: *Blood* Publishing Office, 1900 M Street, NW, Suite 200, Washington, DC 20036.

The appearance of the copyright symbol © at the bottom of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients, for those registered with the Copyright Clearance Center, Inc. (222 Rosewood Drive, Danvers, MA 01923; (978) 750-8400; [www.copyright.com](http://www.copyright.com)). This consent is given on the condition that the copier pay the stated per-copy fee for that article through the Copyright Clearance Center, Inc., for copying beyond that permitted by Sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. For those kinds of purposes, permission must be sought from the Publisher (*see above*).

### Advertising representation

To place orders for product advertisements, classifieds, or commercial reprints, contact Cunningham Associates, 180 Old Tappan Road, Old Tappan, NJ 07675. Telephone: 201-767-4170; fax: 201-767-8065; e-mail: [cunnasso@cybernex.net](mailto:cunnasso@cybernex.net).

The ideas and opinions expressed in *Blood* do not necessarily reflect those of The American Society of Hematology or the Editors of *Blood*. Publication of an advertisement or other product mention in *Blood* should not be construed as an endorsement of the product or the manufacturer's claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. The American Society of Hematology does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of the material contained in this periodical. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on his or her independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient.

### Indexing & abstracting

*Blood* is indexed and abstracted by Index Medicus, Excerpta Medica, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, SCISEARCH, Automatic Subject Citation Alert, ISI/BIOMED, and BIOSIS.

**COVER FIGURE**

**The sites of mutation in hemophilia A are mapped on the structures of the C1 and C2 domains of factor VIII. From the article by Liu et al, beginning on page 979.**

**PLENARY PAPERS**

- 785 **Prolonged survival and tissue trafficking following adoptive transfer of CD4 $\zeta$  gene-modified autologous CD4<sup>+</sup> and CD8<sup>+</sup> T cells in human immunodeficiency virus-infected subjects**  
 R. T. Mitsuyasu, P. A. Anton, S. G. Deeks, D. T. Scadden, E. Connick, M. T. Downs, A. Bakker, M. R. Roberts, C. H. June, S. Jalali, A. A. Lin, R. Pennathur-Das, and K. M. Hege
- 794 **Molecular characterization of a granulocyte macrophage–colony-stimulating factor receptor  $\alpha$  subunit-associated protein, GRAP**  
 J. Tu, N. Karasavvas, M. L. Heaney, J. C. Vera, and D. W. Golde
- 800  **$\alpha$ -Thalassemia resulting from a negative chromosomal position effect**  
 V. M. Barbour, C. Tufarelli, J. A. Sharpe, Z. E. Smith, H. Ayyub, C. A. Heinlein, J. Sloane-Stanley, K. Indrak, W. G. Wood, and D. R. Higgs

**REVIEW ARTICLES**

- 808 **The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies**  
 T. G. Willis and M. J. S. Dyer
- 823 **Erythropoietin, iron, and erythropoiesis**  
 L. T. Goodnough, B. Skikne, and C. Brugnara

**CHEMOKINES**

- 834 **Induction of monocyte- and T-cell-attracting chemokines in the lung during the generation of idiopathic pneumonia syndrome following allogeneic murine bone marrow transplantation**  
 A. Panoskaltis-Mortari, R. M. Strieter, J. R. Hermanson, K. V. Fegeding, W. J. Murphy, C. L. Farrell, D. L. Lacey, and B. R. Blazar
- 840 **LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8**  
 O. M. Z. Howard, H. F. Dong, A.-K. Shirakawa, and J. J. Oppenheim

**CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS**

- 846 **Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range**  
 A. Greinacher, P. Eichler, N. Lubenow, H. Kwasny, and M. Luz
- 852 **Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients**  
 P. Morel, M. Monconduit, D. Jacomy, P. Lenain, B. Grosbois, C. Bateli, T. Facon, I. Dervite, F. Bauters, A. Najman, A. de Gramont, and E. Wattel

- 859 **Constitutive elevation of serum alpha-fetoprotein in Fanconi anemia**  
B. Cassinat, P. Guardiola, S. Chevret, M.-H. Schlageter, M.-E. Toubert,  
J.-D. Rain, and E. Gluckman
- 864 **Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion**  
M. Magni, M. Di Nicola, L. Devizzi, P. Matteucci, F. Lombardi, L. Gandola, F. Ravagnani,  
R. Giardini, G. Dastoli, C. Tarella, A. Pileri, G. Bonadonna, and A. M. Gianni
- 870 **The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score**  
O. Legrand, J.-Y. Perrot, M. Baudard, A. Cordier, R. Lautier, G. Simonin, R. Zittoun,  
N. Casadevall, and J.-P. Marie
- 878 **In vivo generation of human dendritic cell subsets by Flt3 ligand**  
E. Maraskovsky, E. Daro, E. Roux, M. Teepe, C. R. Maliszewski, J. Hoek,  
D. Caron, M. E. Lebsack, and H. J. McKenna

---

**GENE THERAPY**


---

- 885 **Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector**  
V. Dardalhon, S. Jaleco, C. Rebouissou, C. Ferrand, N. Skander, L. Swainson, P. Tiberghien,  
H. Spits, N. Noraz, and N. Taylor
- 894 **Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny**  
C. A. Klug, S. Cheshier, and I. L. Weissman

---

**HEMATOPOIESIS**


---

- 902 **Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo**  
K. D. Bunting, S. Zhou, T. Lu, and B. P. Sorrentino
- 910 **GATA factor transgenes under *GATA-1* locus control rescue germline *GATA-1* mutant deficiencies**  
S. Takahashi, R. Shimizu, N. Suwabe, T. Kuroha, K. Yoh, J. Ohta, S. Nishimura, K.-C. Lim,  
J. D. Engel, and M. Yamamoto
- 917 **Expression of connexin 43 (Cx43) is critical for normal hematopoiesis**  
E. Montecino-Rodriguez, H. Leathers, and K. Dorshkind
- 925 **Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor**  
M. C. Heinrich, D. J. Griffith, B. J. Druker, C. L. Wait, K. A. Ott, and A. J. Zigler
- 933 **JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells**  
S. M. Jacobs-Helber, J. J. Ryan, and S. T. Sawyer
- 941 **A member of Forkhead family transcription factor, FKHL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction**  
Y. Kashii, M. Uchida, K. Kirito, M. Tanaka, K. Nishijima, M. Toshima, T. Ando, K. Koizumi,  
T. Endoh, K.-i. Sawada, M. Momoi, Y. Miura, K. Ozawa, and N. Komatsu

- 950 **Mouse Jagged2 is differentially expressed in hematopoietic progenitors and endothelial cells and promotes the survival and proliferation of hematopoietic progenitors by direct cell-to-cell contact**  
S. Tsai, J. Fero, and S. Bartelmez

**HEMOSTASIS,  
THROMBOSIS, AND  
VASCULAR BIOLOGY**

- 958 **A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor**  
M. Jacquemin, R. Lavend'homme, A. Benhida, B. Vanzieleghem, R. d'Oiron, J.-M. Lavergne, H. H. Brackmann, R. Schwaab, T. VandenDriessche, M. K. L. Chuah, M. Hoylaerts, J. G. G. Gilles, K. Peerlinck, J. Vermeylen, and J.-M. R. Saint-Remy
- 966 **Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis**  
A. Khajuria and D. S. Houston
- 973 **A topological study of the human  $\gamma$ -glutamyl carboxylase**  
J. Tie, S.-M. Wu, D. Jin, C. V. Nicchitta, and D. W. Stafford
- 979 **Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure**  
M.-L. Liu, B. W. Shen, S. Nakaya, K. P. Pratt, K. Fujikawa, E. W. Davie, B. L. Stoddard, and A. R. Thompson
- 988 **The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure**  
R. A. S. Ariëns, H. Philippou, C. Nagaswami, J. W. Weisel, D. A. Lane, and P. J. Grant

**IMMUNOBIOLOGY**

- 996 **Pharmacologic properties of P<sub>27</sub>/P2X<sub>7</sub> receptor characterized in murine dendritic cells: role on the induction of apoptosis**  
O. K. Nihei, A. C. Campos de Carvalho, W. Savino, and L. A. Alves
- 1006 **Interleukin-15 redirects the outcome of a tolerizing T-cell stimulus from apoptosis to anergy**  
H. Dooms, T. Van Belle, M. Desmedt, P. Rottiers, and J. Grooten
- 1013 **A-*myb* rescues murine B-cell lymphomas from IgM-receptor-mediated apoptosis through c-*myc* transcriptional regulation**  
M. Arsura, C. S. Hofmann, J. Golay, M. Introna, and G. E. Sonenshein
- 1021 **CD3 $\zeta$  and CD28 down-modulation on CD8 T cells during viral infection**  
L. A. Trimble, L. W. Kam, R. S. Friedman, Z. Xu, and J. Lieberman
- 1030 **Caspase-independent commitment phase to apoptosis in activated blood T lymphocytes: reversibility at low apoptotic insult**  
C. Dumont, A. Dürrbach, N. Bidère, M. Rouleau, G. Kroemer, G. Bernard, F. Hirsch, B. Charpentier, S. A. Susin, and A. Senik
- 1039 **The PI3 kinase, p38 SAP kinase, and NF- $\kappa$ B signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells**  
K. M. Ardehsna, A. R. Pizzey, S. Devereux, and A. Khwaja

- 1047 **Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses**  
M. H. Hsieh and R. Korngold

- 1056 **Functional characterization of an IL-7-dependent CD4<sup>+</sup>CD8 $\alpha$ <sup>+</sup> Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma**  
E. Poszepczynska, M. Bagot, H. Echchakir, D. Martinvalet, M. Ramez, D. Charue, L. Boumsell, and A. Bensussan

- 1064 **B-cell-autonomous somatic mutation deficit following bone marrow transplant**  
A. M. Glas, E. H. N. van Montfort, J. Storek, E.-G. N. Green, R. P. M. Drissen, V. J. Bechtold, J. Z. Reilly, M. A. Dawson, and E. C. B. Milner

## NEOPLASIA

---

- 1070 **Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance**  
F. X. Mahon, M. W. N. Deininger, B. Schultheis, J. Chabrol, J. Reiffers, J. M. Goldman, and J. V. Melo

- 1080 **Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemia**  
N. Niitsu, J. Okabe-Kado, M. Nakayama, N. Wakimoto, A. Sakashita, N. Maseki, K. Motoyoshi, M. Umeda, and Y. Honma

- 1087 **Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH<sup>-</sup> subgroup of multiple myeloma**  
T. Szczepański, M. B. van 't Veer, I. L. M. Wolvers-Tettero, A. W. Langerak, and J. J. M. van Dongen

- 1094 **TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia**  
N. L. Ramakers-van Woerden, R. Pieters, A. H. Loonen, I. Hubeek, E. van Drunen, H. B. Beverloo, R. M. Slater, J. Harbott, J. Seyfarth, E. R. van Wering, K. Hählen, K. Schmiegelow, G. E. Janka-Schaub, and A. J. P. Veerman

## PHAGOCYTES

---

- 1100 **LSP1 modulates the locomotion of monocyte-differentiated U937 cells**  
Y. Li, Q. Zhang, R. Aaron, L. Hilliard, and T. H. Howard

- 1106 **Molecular analysis of 9 new families with chronic granulomatous disease caused by mutations in CYBA, the gene encoding p22<sup>phox</sup>**  
J. Rae, D. Noack, P. G. Heyworth, B. A. Ellis, J. T. Curnutte, and A. R. Cross

## RED CELLS

---

- 1113 **The molecular defect in hypotransferrinemic mice**  
C. C. Trenor III, D. R. Campagna, V. M. Sellers, N. C. Andrews, and M. D. Fleming

- 1119 **Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation**  
B. N. Y. Setty, S. Kulkarni, A. K. Rao, and M. J. Stuart

- 1125 **Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis**  
G. Montosi, P. Paglia, C. Garuti, C. A. Guzman, J. M. Bastin, M. P. Colombo, and A. Pietrangelo

- 1130 **Triose phosphate isomerase deficiency in 3 French families: two novel null alleles, a frameshift mutation (TPI Alfortville) and an alteration in the initiation codon (TPI Paris)**  
C. Valentin, S. Pissard, J. Martin, D. Héron, P. Labrune, M.-O. Livet, M. Mayer, T. Gelbart, A. Schneider, I. Max-Audit, and M. Cohen-Solal

- 1136 **The human ankyrin-1 gene is selectively transcribed in erythroid cell lines despite the presence of a housekeeping-like promoter**  
P. G. Gallagher, M. Romana, W. T. Tse, S. E. Lux, and B. G. Forget

---

**TRANSFUSION MEDICINE**

- 1144 **Recipient elimination of allogeneic lymphoid cells: donor CD4<sup>+</sup> cells are effective alloantigen-presenting cells**  
L. D. Fast

RECEIVED  
UCF LIBRARY

---

**TRANSPLANTATION**

- 1150 **Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect**  
M. Mielcarek, W. Leisenring, B. Torok-Storb, and R. Storb
- 1157 **Molecular modification of a recombinant anti-CD3 $\epsilon$ -directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model**  
D. A. Vallera, D. W. Kuroki, A. Panoskaltisis-Mortari, D. J. Buchsbaum, B. E. Rogers, and B. R. Blazar
- 1166 **A novel application of cyclosporine A in nonmyeloablative pretransplant host conditioning for allogeneic BMT**  
B. Nikolic, G. Zhao, K. Swenson, and M. Sykes

APR 17 2000

Serials

---

**BRIEF REPORTS**

- 1173 **Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver**  
F. Park, K. Ohashi, and M. A. Kay
- 1177  **$\alpha$ -Fibrinogen Thr312Ala polymorphism and venous thromboembolism**  
A. M. Carter, A. J. Catto, H. P. Kohler, R. A. S. Ariëns, M. H. Stickland, and P. J. Grant
- 1180 **Splenectomy selectively affects the distribution and mobility of the recirculating lymphocyte pool**  
T. J. Seabrook, W. R. Hein, L. Dudler, and A. J. Young
- 1184 **Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab**  
V. R. Sharma, D. R. Fleming, and S. P. Slone
- 1187 **Ligation of the CD44 adhesion molecule inhibits drug-induced apoptosis in human myeloid leukemia cells**  
M. Allouche, R. S. Charrad, A. Bettaieb, C. Greenland, C. Grignon, and F. Smadja-Joffe
- 1191 **Familial thrombophilia associated with fibrinogen Paris V: Dusart syndrome**  
T. Tarumi, D. Martincic, A. Thomas, R. Janco, M. Hudson, P. Baxter, and D. Gailani

- 1194 **Cytomegalovirus infection following transplantation of autologous CD34-selected progenitor cells**  
G. J. Schiller, R. Vescio, and J. Berenson
- 1194 **Cyclosporine (CSP) or CSP plus methylprednisolone for graft-versus-host-disease prophylaxis in patients with high-risk lymphohemopoietic malignancies: long-term follow-up of a randomized trial**  
H. J. Deeg, M. E. D. Flowers, W. Leisenring, F. R. Appelbaum, P. J. Martin, and R. F. Storb
- 1196 **The limitations of site-directed mutagenesis in the localization of Rh D epitopes**  
T. Y. Chang and D. L. Siegel
- 1197 **Response: limitations of prediction of epitope structure from corresponding antibody sequence**  
N. D. Avent, W. Liu, J. W. Jones, M. L. Scott, and D. Voak
- 1199 **A potential role for leukemia inhibitory factor in the increased clonogenicity of human fetal progenitor cells**  
P. Kurre and S. Burdach
- 1200 **Response: leukemia inhibitory factor does not have a direct effect on the expansion of transplantable human hematopoietic stem cells**  
C.-C. Shih and S. J. Forman

## SPECIAL DEPARTMENTS

- xix **Author guide**
- xxxii **Future articles**
- 807 **Erratum in Brugger et al. Positively selected autologous blood CD34<sup>+</sup> cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. *Blood*. 1994;84:1421-1426.**
- 863 **Erratum in Bang et al. Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MCH antigens. *Blood*. 2000;95:1735-1742.**
- 987 **Erratum in Alcobia et al. Spatial associations of centromeres in the nuclei of hematopoietic cells: evidence for cell-type-specific organizational patterns. *Blood*. 2000;95:1608-1615.**
- 1202 **Announcements**

Manuscripts to be considered for publication in *Blood* should be sent to our **new** address:

**Kenneth Kaushansky, MD**  
Editor-in-Chief,  
*Blood*, Journal of the  
American Society of Hematology  
1900 M Street, NW, Suite 200  
Washington, DC 20036

For other information, call (202) 776-0548. All manuscripts submitted to *Blood* and subsequently accepted for publication will be assessed a \$50 charge per published page. This charge is necessary to offset the increasing cost of publication.



# blood

JOURNAL OF  
THE AMERICAN  
SOCIETY OF  
HEMATOLOGY

ASSOCIATE EDITORS  
Frederick R. Appelbaum, *Seattle, WA*  
H. Franklin Bunn, *Boston, MA*  
Michael L. Cleary, *Stanford, CA*  
Cynthia Dunbar, *Washington, DC*  
Connie J. Eaves, *Vancouver, Canada*  
Willem E. Fibbe, *Leiden, The Netherlands*

Tomas Ganz, *Los Angeles, CA*  
Jerome E. Groopman, *Boston, MA*  
Dan L. Longo, *Baltimore, MD*  
J. Evan Sadler, *St. Louis, MO*  
Sanford J. Shattil, *La Jolla, CA*

2000 EDITORIAL  
BOARD

Janis L. Abkowitz, *Seattle, WA*  
Raymond V. Alexanian, *Houston, TX*  
Claudio Anasetti, *Seattle, WA*  
Nancy Andrews, *Boston, MA*  
Hava Avraham, *Boston, MA*  
Grover C. Bagby, Jr., *Portland, OR*  
Glenn Begley, *Perth, Australia*  
Kapil N. Bhalla, *Tampa, FL*  
Barbara E. Bierer, *Bethesda, MD*  
David M. Bodine, *Bethesda, MD*  
Robert M. Bookchin, *Bronx, NY*  
Niels Borregaard, *Copenhagen, Denmark*  
Lawrence F. Brass, *Philadelphia, PA*  
Malcolm K. Brenner, *Memphis, TN*  
Carlo Brugnara, *Boston, MA*  
Samuel Burstein, *Oklahoma City, OK*  
Raju Chaganti, *New York, NY*  
Richard Champlin, *Houston, TX*  
Laure Coulombel, *Paris, France*  
Riccardo Dalla-Favera, *New York, NY*  
H. Joachim Deeg, *Seattle, WA*  
John Dick, *Toronto, Canada*  
Brian Druker, *Portland, OR*  
Stephen G. Emerson, *Philadelphia, PA*  
Joan E. B. Fox, *Cleveland, OH*  
David Gailani, *Nashville, TN*  
D. Gary Gilliland, *Boston, MA*  
Gordon Ginder, *Richmond, VA*  
John G. Gribben, *Boston, MA*  
Katherine Hajjar, *New York, NY*  
Derek Hart, *South Brisbane, Australia*  
Robert Hromas, *Indianapolis, IN*  
Keith Humphries, *Vancouver, Canada*  
Graham A. Jamieson, *Rockville, MD*  
Marshall E. Kadin, *Boston, MA*  
William F. Kane, *Durham, NC*  
Donald B. Kohn, *Los Angeles, CA*  
Margot S. Kruskal, *Boston, MA*  
Gerald Krystal, *Vancouver, Canada*  
Joanne Kurtzberg, *Durham, NC*  
Larry W. Kwak, *Bethesda, MD*  
Timothy J. Ley, *St. Louis, MO*  
Jonathan Licht, *New York, NY*

Alan K. Lichtenstein, *Los Angeles, CA*  
Bing Lim, *Boston, MA*  
John Lollar, *Atlanta, GA*  
Michael W. Long, *Ann Arbor, MI*  
Angel Lopez, *Adelaide, Australia*  
Philip Low, *West Lafayette, IN*  
Lucio Luzzatto, *New York, NY*  
Robert M. Lyons, *San Antonio, TX*  
Harry L. Malech, *Bethesda, MD*  
William Stratford May, *Galveston, TX*  
Anna Rita Migliaccio, *New York, NY*  
Atsushi Miyajima, *Tokyo, Japan*  
James H. Morrissey, *Oklahoma City, OK*  
Mohandas Narla, *Berkeley, CA*  
Stephen D. Nimer, *New York, NY*  
John O'Shea, *Bethesda, MD*  
David Pellman, *Boston, MA*  
John C. Reed, *La Jolla, CA*  
Dan Rosenblum, *Kensington, MD*  
Gerald J. Roth, *Seattle, WA*  
Stephen J. Russell, *Rochester, MN*  
Samuel A. Santoro, *St. Louis, MO*  
John W. Schrader, *Vancouver, Canada*  
Saul J. Sharkis, *Baltimore, MD*  
Ethan Shevach, *Bethesda, MD*  
Elizabeth Shpall, *Denver, CO*  
Roy L. Silverstein, *New York, NY*  
Elaine Sloand, *Bethesda, MD*  
Edward L. Snyder, *New Haven, CT*  
Paul Sondel, *Madison, WI*  
Brian Sorrentino, *Memphis, TN*  
Gerald J. Spangrude, *Salt Lake City, UT*  
Harald Stein, *Berlin, Germany*  
Martin S. Tallman, *Chicago, IL*  
Michael J. A. Tanner, *Bristol, United Kingdom*  
Marilyn J. Telen, *Durham, NC*  
Daniel G. Tenen, *Boston, MA*  
Brian Van Ness, *Minneapolis, MN*  
Jerry Ware, *La Jolla, CA*  
Raymond P. Warrell, Jr., *New York, NY*  
Yu-Chung Yang, *Indianapolis, IN*  
Hagop Youssoufian, *Houston, TX*  
Leonard I. Zon, *Boston, MA*

EDITOR-IN-CHIEF

**Kenneth Kaushansky**  
*Seattle, WA*

EDITORIAL OFFICE  
Washington, DC

*Interim Managing Editor:*  
Andrew Harmon

*Editorial Assistants:*  
Louise Quinn  
Nicole Gray  
Helen Okeke  
Carolyn Elliott

PUBLISHING OFFICE  
Washington, DC

*Director of Publishing:*  
Sabine J. Beisler

*Production Manager:*  
Todd D. Reitzel

*Production Editors:*  
Karen S. Mason  
Megan E. O'Reilly  
Trish Weisman

*Production Assistant:*  
Nichole S. Merkt

*Marketing Assistant:*  
Margo R. Meyerhoff

PAST EDITORS

William Dameshek  
(1946-1969)

Ernst R. Jaffé  
(1975-1977)

John W. Adamson  
(1983-1987)

James D. Griffin  
(1993-1997)

Frederick Stohlman, Jr.  
(1970-1974)

Paul A. Marks  
(1978-1982)

Arthur W. Nienhuis  
(1988-1992)

# Prolonged survival and tissue trafficking following adoptive transfer of CD4 $\zeta$ gene-modified autologous CD4<sup>+</sup> and CD8<sup>+</sup> T cells in human immunodeficiency virus–infected subjects

Ronald T. Mitsuyasu, Peter A. Anton, Steven G. Deeks, David T. Scadden, Elizabeth Connick, Matthew T. Downs, Andreas Bakker, Margo R. Roberts, Carl H. June, Sayeh Jalali, Andy A. Lin, Rukmini Pennathur-Das, and Kristen M. Hege

We have genetically engineered CD4<sup>+</sup> and CD8<sup>+</sup> T cells with human immunodeficiency virus (HIV) specificity by inserting a gene, CD4 $\zeta$ , containing the extracellular domain of human CD4 (which binds HIV *env*) linked to the zeta ( $\zeta$ ) chain of the T-cell receptor (which mediates T-cell activation). Twenty-four HIV-positive subjects received a single infusion of 2 to 3  $\times$  10<sup>10</sup> autologous CD4 $\zeta$ -modified CD4<sup>+</sup> and CD8<sup>+</sup> T cells administered with (n = 11) or without (n = 13) interleukin-2 (IL-2). Subjects had CD4 counts greater than 50/ $\mu$ L and viral loads of at least 1000

copies/mL at entry. T cells were costimulated *ex vivo* through CD3 and CD28 and expanded for approximately 2 weeks. CD4 $\zeta$  was detected in 1% to 3% of blood mononuclear cells at 8 weeks and 0.1% at 1 year after infusion, and survival was not enhanced by IL-2. Trafficking of gene-modified T cells to bulk rectal tissue and/or isolated lamina propria lymphocytes was documented in a subset of 5 of 5 patients at 14 days and 2 of 3 at 1 year. A greater than 0.5 log mean decrease in rectal tissue–associated HIV RNA was observed for at least 14 days, suggesting

compartmental antiviral activity of CD4 $\zeta$  T cells. CD4<sup>+</sup> counts increased by 73/ $\mu$ L at 8 weeks in the group receiving IL-2. There was no significant mean change in plasma HIV RNA or blood proviral DNA in either treatment arm. This sustained, high-level persistence of gene-modified T cells demonstrates the feasibility of *ex vivo* T-cell gene therapy in HIV-infected adults and suggests the importance of providing HIV-specific T-helper function. (Blood. 2000;96:785-793)

© 2000 by The American Society of Hematology

## Introduction

Much experimental and observational data suggest that the T-cell immune response plays a major role in containment of human immunodeficiency virus (HIV) during acute and chronic infection. The emergence of HIV-specific CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) coincides with the rapid decrease in plasma viremia during acute infection, and the frequency of HIV *env*-specific CTLs is inversely correlated with plasma viral load and the rate of decline in CD4<sup>+</sup> T-cell counts.<sup>1,2</sup> Furthermore, a decline in HIV-specific CD8<sup>+</sup> T cells occurs in patients as they progress to later stages of the disease.<sup>3</sup> Most HIV-1–infected long-term nonprogressors have high circulating levels of HIV-1–specific CTL precursors,<sup>4,5</sup> and increased HIV-specific CTLs as well as high HIV-specific CD4<sup>+</sup> T-cell proliferative responses have been demonstrated in HIV-exposed seronegative subjects.<sup>6,7</sup> The most direct evidence of the role of CD8<sup>+</sup> T cells in HIV infection comes from recent studies of CD8<sup>+</sup> T-cell depletion in acute and chronically infected macaques with simian immunodeficiency virus (SIV). In the setting of chronic SIV infection, CD8<sup>+</sup> T-cell depletion led to a rapid 1- to 4-log increase in plasma viral load, which returned to baseline coincident with recovery of CD8<sup>+</sup> T cells in the blood.<sup>8</sup> Following acute SIV infection, CD8<sup>+</sup> T-cell depletion led to longer persis-

tence of high-level viremia and a more rapidly progressive disease course compared with nondepleted monkeys.<sup>9</sup>

Animal and human experiments in chronic viral infection have demonstrated that antigen-specific CD4<sup>+</sup> T-cell responses are critical for maintenance of CTLs and eradication of viral infection.<sup>10,11</sup> Most studies have shown HIV-specific CD4<sup>+</sup> T-cell proliferative responses to be absent or low in patients with chronic, progressive HIV infection.<sup>12,13</sup> Following initiation of combination highly active antiretroviral therapy (HAART), the recovery of HIV-specific CD4<sup>+</sup> T-helper cell responses has been observed only in patients treated very early after acute infection.<sup>14</sup> Vigorous HIV-specific CD4<sup>+</sup> responses have been associated with control of viremia in the absence of drug therapy and clinical long-term nonprogression.<sup>14</sup> Although recent flow cytometry–based studies have demonstrated the presence of HIV-specific CD4<sup>+</sup> T cells in the majority of actively infected individuals, functional enhancement is still likely to be necessary for optimal defense against HIV.<sup>15</sup> In total, these data suggest that both arms of the host cellular immune response are necessary for containment of HIV.

Immunotherapy of viral infection with the use of antigen-specific T cells has been studied in the setting of cytomegalovirus

From the University of California, Los Angeles, CA; San Francisco General Hospital, San Francisco, CA; Massachusetts General Hospital, Boston, MA; University of Colorado Health Science Center, Denver, CO; Statistics Collaborative, Washington DC; Specialty Labs, Los Angeles, CA; University of Virginia, Charlottesville, VA; University of Pennsylvania, Philadelphia, PA; and Cell Genesys, Inc, Foster City, CA.

Submitted December 8, 1999; accepted March 12, 2000.

Supported by Cell Genesys Inc in collaboration with Hoechst Marion Roussel. P.A.A. was supported in part by Mucosal Immunology CORE Grant no. AI28697, University of California, Los Angeles. This work was carried out in part

in the General Clinical Research Centers at the following institutions: University of California, Los Angeles (RR-00865), San Francisco General Hospital (5-MO1-RR00083-37), and University of Colorado Health Science Center (RR-00051).

**Reprints:** Kristen M. Hege, Cell Genesys, Inc, 342 Lakeside Dr, Foster City, CA 94404; e-mail: kristenh@cellgenesys.com.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2000 by The American Society of Hematology

(CMV), Epstein-Barr virus (EBV), and HIV. Adoptive transfer of allogeneic CMV-specific<sup>10,16</sup> or EBV-specific<sup>17-19</sup> T cells in bone marrow transplant recipients has resulted in recovery of virus-specific CTL activity, reduction of viremia, and effective prophylaxis or treatment of CMV- and EBV-induced disease. Endogenous recovery or adoptive transfer of antigen-specific CD4<sup>+</sup> T cells was required for long-term maintenance of transferred CMV- or EBV-specific CTLs.<sup>19,20</sup> Thus, adoptive immunotherapy with antigen-specific T cells is likely to require co-infusion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells to achieve optimal *in vivo* survival and activity.

Adoptive transfer of HIV-specific T cells has potential as immunotherapy for HIV infection. Strategies to date have focused on *ex vivo*-expanded autologous HIV-specific CD8<sup>+</sup> monoclonal or polyclonal T cells.<sup>21-24</sup> Rather than isolating and expanding rare T-cell clones with major histocompatibility complex (MHC)-restricted antigenic specificity, a method has been developed to generate large numbers of HIV-specific primary T cells rapidly using retroviral-mediated gene transfer to insert an HIV-targeting gene (CD4 $\zeta$ ).<sup>25</sup> CD4 $\zeta$  is a genetically engineered, MHC-unrestricted, chimeric immune receptor composed of the zeta ( $\zeta$ ) subunit of the CD3 T-cell receptor (the cytoplasmic domain involved in signal transduction) fused to the transmembrane and extracellular domains of human CD4 (which targets HIV *env* expressed on the surface of infected cells). The MHC-unrestricted nature of this chimeric receptor allows HIV-specific targeting of both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. This may also circumvent the potential ability of HIV to evade the T-cell immune response through down-regulation of HLA molecules on the surface of infected cells.<sup>26-28</sup>

Preclinical studies of CD4 $\zeta$  gene-modified CD8<sup>+</sup> T cells have demonstrated antigen-specific proliferation and cytokine production, cytolytic activity against HIV-infected T cells, and inhibition of viral replication in HIV-infected macrophages equivalent to that seen with naturally occurring HIV-specific CTL clones.<sup>25,29</sup> Preliminary studies of adoptive transfer of *ex vivo*-expanded CD4 $\zeta$ -modified syngeneic CD8<sup>+</sup> T cells in HIV-infected twin pairs demonstrated a rapid decline in gene-marked cells in the blood, suggesting a lack of HIV-specific CD4<sup>+</sup> T-cell help to maintain the transferred CTLs.<sup>30</sup> Recent advances in *ex vivo* culture methods have allowed us to develop an efficient *ex vivo* T-cell stimulation and gene transfer system that yields mixed populations of gene-modified CD4<sup>+</sup> and CD8<sup>+</sup> T cells.<sup>31</sup> We now report the data from a phase II clinical trial of co-infusion of autologous CD4 $\zeta$ -modified CD4<sup>+</sup> and CD8<sup>+</sup> T cells administered with or without exogenous interleukin-2 (IL-2) in 24 HIV-infected patients with detectable viral loads.

## Patients and methods

### Subjects

HIV-seropositive individuals over the age of 13 years on stable antiretroviral therapy for more than 8 weeks with viral loads of 1000 to 100 000 copies/mL and CD4 counts greater than 50/ $\mu$ L were enrolled in this study between May and December 1997. Informed consent was obtained in accordance with institutional review board guidelines. Patients were excluded for significant comorbid illness, active opportunistic infection or malignancy, or recent history of treatment with immunomodulatory agents.

### Vector production

The CD4 $\zeta$  retroviral vector rkat4.2SVGF3e- is a variant of the previously described rkat43.3F3 vector and was constructed using the pBR322 plasmid and a murine maloney leukemia virus (MLLV) backbone.<sup>32</sup> This vector codes for a chimeric receptor gene composed of the extracellular and transmembrane domains of human CD4 linked to the cytoplasmic domain of the CD3 T-cell receptor  $\zeta$  chain. The vector titer on NIH 3T3 cells ranged from 2 to 15  $\times$  10<sup>6</sup> viruses/mL. Master and working cell banks and vector lots all tested negative for replication competent retrovirus (RCR) by supernatant amplification and cocultivation on *Mus dunni* cells.<sup>33</sup>

### T-cell processing

Lymphapheresis was performed locally using an automated cell separator (Cobe Spectra or CS-3000, Lakewood, CO) with processing of 6 to 10 L of blood to achieve a minimum of 5  $\times$  10<sup>9</sup> peripheral blood mononuclear cells (PBMCs). Apheresis products were shipped to Cell Genesys, Foster City, CA, at room temperature and processed within 24 hours of receipt. PBMCs were isolated by density gradient separation using a Stericell device (Haemonetics, Braintree, MA). Recovered cells were stimulated using magnetic beads (Dyna, Oslo, Norway) coated with anti-CD3 (OKT3) and anti-CD28 (monoclonal antibody 9.3), at a bead to cell ratio of 3:1, in serum-free AIM-V medium (Gibco, Long Island, NY) containing IL-2 (200 IU/mL; Chiron, Emeryville, CA) and antiretroviral agents (1  $\mu$ mol/L zidovudine, Burroughs Wellcome, Research Triangle, NC; 10  $\mu$ mol/L didanosine, Bristol Myers Squibb, Princeton, NJ; and 500  $\mu$ mol/L ritonavir, Abbott Laboratories, Chicago, IL). On day 3, the beads were removed using a Maxsep magnetic bead separator (Baxter, Roundlake, IL) and resuspended in AIM-V medium with IL-2 and ritonavir. Transduction with CD4 $\zeta$  retroviral supernatant at a multiplicity of infection of 2 viral particles per cell was performed on days 5 and 7 in AIM-V medium containing IL-2, ritonavir, and polybrene (Aldrich, St Louis, MO). Supernatant was removed by centrifugation using a SteriCell harvester, and cell expansion in AIM-V medium with IL-2, zidovudine, didanosine, and ritonavir continued until the target cell dose of 3  $\times$  10<sup>10</sup> was obtained (days 10-17). The final T-cell products were cryopreserved in 50-mL bags containing 6  $\times$  10<sup>9</sup> cells/bag in Plasmalyte-A (Baxter IV Systems, Roundlake, IL) with 10% dimethylsulfoxide (Sigma, St Louis, MO), 1% dextran-40 (Baxter IV Systems), and 5% human serum albumin (Alpha Therapeutics, Los Angeles, CA), and stored in liquid nitrogen. Final T-cell products were tested for viability (by trypan blue exclusion), sterility, *Mycoplasma*, transduction efficiency (CD4 $\zeta$  presence by polymerase chain reaction [PCR]), HIV replication (p24 enzyme-linked immunosorbent assay; NEN Life Sciences, Boston, MA), RCR (cocultivation on *M dunni* cells), and HIV-specific CTL activity. Cytolytic activity was assessed in a standard cytotoxic T-lymphocyte assay with 293 cells (human embryonic kidney line) expressing HIV *env* as cytolytic targets.<sup>25</sup> Phenotypic analysis was performed using antibodies to CD3, CD4, CD8, CD28 (Coulter, Miami, FL), CD25 (Caltag, Burlingame, CA), and CD62L (PharMingen, San Diego, CA). Cryopreserved T cells were thawed in a 37°C water bath at the patient's bedside and infused directly through a peripheral intravenous catheter over 5 to 10 minutes per bag.

### Treatment, toxicity, and response evaluation

Subjects were randomized to receive a single intravenous infusion of 2 to 3  $\times$  10<sup>10</sup> CD4 $\zeta$  gene-modified T cells administered with or without exogenous IL-2. IL-2 was administered as a 5-day continuous intravenous infusion at a dose of 6 million IU/24 hours, beginning 4 hours before the T-cell infusion. All subjects were followed for at least 8 weeks after the T-cell infusion and monitored for toxicity, changes in plasma HIV viral load (ultrasensitive Roche Amplicor kit, sensitivity 40 copies/mL), HIV proviral DNA (HIV DNA PCR; Specialty Labs, Los Angeles, CA), CD4<sup>+</sup> T-cell count, and gene-modified T-cell persistence in peripheral blood (CD4 $\zeta$  DNA PCR; Specialty Labs). A subset of 5 patients was monitored for rectal mucosa-associated viral burden and tissue trafficking of CD4 $\zeta$  T cells. Follow-up was extended to 1 year in 18 of 24 subjects.

## CD4 $\zeta$ T-cell survival and gene expression

**CD4 $\zeta$  DNA PCR.** PBMCs were isolated by standard Ficoll gradient separation. In a subset of patients, immunoselection for CD4 $^{+}$  and CD8 $^{+}$  T cells was performed before PCR analysis. Immunoselection of CD8 $^{+}$  T cells from whole blood was performed by first depleting monocytes using anti-CD14-coated beads (Dynal) followed by positive selection with anti-CD8-coated beads (> 95% purity). Immunoselection for CD4 $^{+}$  T cells was performed by first depleting monocytes and CD8 $^{+}$  T cells from the samples using anti-CD14- and anti-CD8-coated beads followed by positive selection with anti-CD4-coated beads (> 95% purity). DNA was recovered by phenol-chloroform extraction and ethanol precipitation. Quantitation of globin and CD4 $\zeta$  copy number was performed by real-time PCR on an ABI Prizm 7700 instrument (Taqman PCR; Perkin-Elmer Applied Biosystems, Foster City, CA). Primers for CD4 $\zeta$  PCR amplify a region spanning  $\zeta$  and the 3' untranslated region and are as follows: forward primer, 5'-ACC CGG TTC ACT CTT CTC AG-3'; reverse primer, 5'-ACA GGT GGG GTC TTT CAT TC-3'; and internal probe, 5'-(FAM) CAC AGA CTG TTG TCC CTG CAC TCT (TAMRA)-3'. PCR reactions were carried out with the Taqman PCR reagent kit (Perkin-Elmer Applied Biosystems). Amplification was performed for 45 cycles (initial activation: 94°C, 10 minutes; cycling: 94°C, 15 seconds, 57.5°C, 45 seconds). Copy number was determined using normal PBMC DNA as a beta-globin standard and CD4 $\zeta$  PCR product as the standard for CD4 $\zeta$  quantitation. Assay sensitivity was 117 copies/10 $^6$  cells.

**CD4 $\zeta$  RNA reverse transcriptase (RT)-PCR.** Total RNA was isolated from PBMC pellets using TriReagent (Molecular Research Center, Cincinnati, OH) following the manufacturer's protocol; cDNA was prepared using Superscript II reverse transcriptase (Life Technologies, Long Island, NY). Samples were incubated at 48°C for 90 minutes and then digested with RNase H at 37°C. RNA isolated from PBMC pellets from HIV-negative human donors was used as a control. PCR amplifications were performed using TaqMan technology, as described earlier. CD4 $\zeta$  PCR product was used to generate a CD4 $\zeta$  standard curve. To normalize results for the efficiency of mRNA isolation, we amplified reduced glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in a separate Taqman PCR reaction and used it to generate a standard reference series. Data analyses for CD4 $\zeta$  and GAPDH amplifications were performed using the Sequence Detection System software (version 1.6.3) default settings.

## HIV proviral DNA assay

DNA was isolated from PBMCs, and quantification of globin and HIV-1 proviral DNA copy number was performed by Taqman PCR, as described for CD4 $\zeta$  DNA PCR. Primers sequences recognized HIV *gag* and were as follows: forward primer, 5'-CTC TAA GAG CCG AGC AAG CTT C-3'; reverse primer, 5'-GGT CCT CCT ACT CCC TGA CAT-3'; and internal probe, 5'-(FAM)-AAG CAT TGG GAC CAG CGG CTA CAC T-(TAMRA)-3'. Amplification was performed for 50 cycles with the same cycling conditions as for CD4 $\zeta$  DNA PCR. Plasmid BH10 $^{34}$  was used as a standard for HIV-1 DNA copy number quantification. BH10 contains a replication-defective copy of the HIV-1 subtype B isolate HxB2. Assay sensitivity was 35 copies/10 $^6$  cells.

## Replication-competent retrovirus (RCR) testing in patients

Analysis for RCR was performed using Taqman PCR. Genomic DNA was isolated from PBMCs using the Puregene kit (Gentra Systems, Minneapolis, MN) following the manufacturer's protocol. PCR primers S-RCR-F1 (5'-GGG ACA CGG GAT GCT CTA AA) and S-RCR-R1 (5'-GGA AGG AAT TGG ATA CTT TGG AGA) amplify a 70-bp sequence in the envelope region of the amphotropic murine leukemia virus. AmpErase (UNG, 0.5U) was included in the PCR reaction. PCR amplifications were performed in an ABI Prizm 7700 instrument using the following cycling conditions: 50°C  $\times$  2 minutes, 95°C  $\times$  10 minutes, 95°C  $\times$  15 seconds, and 60°C  $\times$  1 minute (40 cycles). Data analysis was performed using the Sequence Detection System software, as described previously. A 466-bp PCR product derived from the MMLV plasmid pkat2Ampac.Utd was used to generate a standard

curve in triplicate (1-1000 template copies) for assay quantitation. Assay sensitivity was 7 copies/10 $^6$  cells.

## Rectal biopsy substudy

Patients enrolled at the University of California, Los Angeles were eligible for a substudy to analyze serial biopsies of rectal mucosa for viral burden and the presence of CD4 $\zeta$ -modified T cells.

**Biopsy acquisition.** Flexible sigmoidoscopy was performed 1 week before T-cell infusion and at days 3, 7, and 14 after infusion. At each procedure, 10 biopsies (large-cup, 3.3 OD, 8 mm span; Microvasive) were obtained circumferentially at a standard level of 30 cm. Each biopsy was approximately 2 to 3  $\mu$ L. Six biopsy specimens were immediately frozen in liquid nitrogen and stored at -80°C. Four specimens were placed in RPMI medium for subsequent isolation of mucosal mononuclear cells.

**Isolation of mucosal mononuclear cells for CD4 $\zeta$  analysis.** Four biopsy specimens in RPMI 1640 medium were transferred into a sterile petri dish containing Ca $^{2+}$ /Mg $^{2+}$ -free phosphate-buffered saline (PBS) supplemented with 50  $\mu$ mol/L 2-mercaptoethanol and 100 mmol/L EDTA, and teased apart using two 18G needles. The dispersed tissue was incubated at 37°C in a shaking water bath for 20 minutes, washed twice with PBS, resuspended in 0.1 mg/mL of collagenase/dispase (Boehringer Mannheim, Indianapolis, IN) in RPMI 1640, and further incubated at 37°C with shaking for 60 minutes. The digested tissue was repeatedly aspirated through an 18G followed by a 20G needle and filtered through a 70- $\mu$  cell strainer to yield a single cell suspension. Mononuclear cells were enumerated visually, and viability was assessed by trypan blue exclusion. Absolute cell numbers were confirmed by flow cytometry with the use of TruCount beads (Becton Dickinson, San Jose, CA). These techniques yielded an average of 0.2 to 5.0  $\times$  10 $^5$  CD45 $^{+}$  mononuclear cells, 1.0 to 4.0  $\times$  10 $^4$  CD4 $^{+}$  T cells, and 1.0 to 8.0  $\times$  10 $^4$  CD8 $^{+}$  T cells per 4 biopsies.<sup>35</sup>

**HIV RNA analysis of bulk rectal tissue.** Biopsies from each patient were homogenized (Powergen homogenizer; Fisher Scientific, Pittsburgh, PA) and Trizol-extracted (Gibco), with separation of RNA and DNA phases to ensure that RNA for viral load assays and DNA for CD4 $\zeta$  analysis were from the same biopsy. RNA was further extracted with the Rneasy kit (Qiagen, Valencia, CA). All analyses were performed on 2 biopsy specimens extracted independently and run in duplicate.<sup>36,37</sup> RT-PCR for HIV RNA was performed using the ThermoStable rTth Reverse Transcriptase RNA PCR kit (Perkin-Elmer) with oligonucleotide primer pairs 667/AA55 specific for the R/U5 region of HIV LTR RNA and was designed to capture both unspliced and multiply spliced HIV RNA.<sup>38</sup> Primer 667 was radiolabeled using T4 kinase with  $^{32}$ P. A linear standard curve was generated by amplifying the in vitro synthesized HIV LTR RNA sequences diluted in seronegative tissue RNA. Percentage RNA recovery was estimated using seronegative frozen biopsies with known quantities of a synthesized 140-bp sequence recognized by the 667/AA55 primers and was greater than 95%. PCR products were quantified using the Ambis Image Analysis System. Sensitivity was 10 copies/ $\mu$ g RNA.

**CD4 $\zeta$  PCR assay.** DNA was extracted from frozen rectal biopsies and mucosal mononuclear cells using Trizol reagent, as described earlier, with DNA subsequently isolated by ethanol precipitation with 2 washes in 0.1 mol/L sodium citrate/10% ethanol buffer. Isolated DNA was transferred to Cell Genesys for amplification of CD4 $\zeta$  DNA.

## Statistical analysis

Treatment groups were compared for differences in absolute levels and changes from baseline for each efficacy end point with a 2-sample Student *t* test and a 2-sample Wilcoxon test, and adjustment was made for multiple correlated comparisons. Undetectable values for efficacy end points were set to 50% of the detection limit for the purposes of analysis. For change from baseline analyses, an average of 2 preinfusion values (week -1 and week 0) was used to calculate the baseline. Adverse events were coded using the fifth edition of the Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART).


## Results

### Patient characteristics and treatment

Twenty-five patients were enrolled in the study between May 29, 1997, and December 3, 1997. One patient was removed from the study before cell infusion because of failure of T-cell processing. Twenty-four patients received cell infusions and completed 8 weeks of follow-up. Eleven patients were randomized to receive a single infusion of  $2$  to  $3 \times 10^{10}$  CD4 $\zeta$ -modified T cells plus IL-2 (6 million IU/24 hours by continuous intravenous infusion  $\times$  5 days), and 13 were randomized to receive CD4 $\zeta$ -modified T cells alone. Table 1 lists the patient demographics and baseline laboratory data for the 24 treated patients. The majority of patients were male, white, and 30 to 50 years of age, and had an excellent performance status. Twenty (83%) had been diagnosed with HIV infection more than 3 years before enrollment. Mean viral load at enrollment was 20 137 copies/mL and mean CD4 $^+$  T-cell count was 332/ $\mu$ L. There were no statistically significant differences between the treatment groups for any screening covariates. One patient was taking no antiretroviral drugs and 23 (96%) were taking stable antiretroviral medications from at least 8 weeks before cell infusion through 8 weeks of follow-up, with 1 exception (switch from lamivudine/indinavir to saquinavir/nelfinavir 36 days after infusion). Twenty (83%) were taking protease inhibitors, 6 (25%) were taking non-nucleoside reverse transcriptase inhibitors, and 7 (29%) were taking hydroxyurea.

### Characteristics of CD4 $\zeta$ T-cell products

CD4 $\zeta$ -modified T cells were successfully processed and released in 24 of 25 patients. A total of 27 lymphapheresis products were processed, and the T-cell growth curves are shown in Figure 1. Two patients underwent repeat apheresis because of initial culture failure, and 1 was successfully processed the second time. A



**Figure 1.** T-cell growth curves of 27 autologous CD4 $\zeta$ -modified CD4 $^+$  and CD8 $^+$  T-cell products in 25 enrolled subjects. The minimum starting cell count was  $5 \times 10^9$ . Transduction with CD4 $\zeta$  retroviral supernatant occurred on days 5 and 7, followed by expansion in serum-free medium containing IL-2 (200 IU/mL) and antiretroviral agents until reaching the target cell dose of  $3 \times 10^{10}$  cells (horizontal line on chart). Cell processing was successful in 24 of 25 subjects (the 2 failed cultures are depicted with the dashed lines). Both patients underwent repeat lymphapheresis, and 1 was successfully processed the second time.

common feature of the 3 failed cultures was a low lymphocyte content of the incoming apheresis products.

Characteristics of the 24 successful T-cell products are shown in Table 2. Cells were expanded ex vivo for an average of 13 days, and all cultures were completed within 17 days. This yielded a mean of  $4.2 \times 10^{10}$  cells (range,  $1.9$ - $6.8 \times 10^{10}$  cells). Average transduction efficiency as measured by PCR for CD4 $\zeta$  was 19% and ranged from 5% to 57%. The average PCR composition of the final T-cell products yielded a ratio of CD8 to CD4 T cells of

**Table 1.** Patient characteristics

Characteristic	Cells + IL-2 (n = 11)	Cells only (n = 13)	Total (n = 24)	P value
Age, y				
Mean	42	39	40	.22
Range	37-49	29-50	29-50	
Gender				.22
Male	11	10	21	
Female	0	3	3	
Ethnic group				.56
White	8	11	19	
African American	0	1	1	
Hispanic	2	1	3	
Other	1	0	1	
Viral load (copies/mL)				.61
Mean	24 217	16 685	20 137	
Range	1241-73 282	2351-86 943	1241-86 943	
CD4 $^+$ count (/mm $^3$ )				.39
Mean	288	369	332	
Range	114-639	125-827	114-827	
KPS (%)				.39
90	5	3	8	
100	6	10	16	
HIV infection, y				.63
1-3	1	3	4	
>3	10	10	20	

KPS, Karnofsky Performance Status.

**Table 2.** T-cell manufacturing data

Patient ID	CD4 (%)*	CD8 (%)*	CD62L (%)*	CD28 (%)*	CD25 (%)*	Culture days†	CD4 $\zeta$ by PCR‡
N215	24	73	83	88	—	13	11
H202	62	38	96	98	88	12	17
C211	17	80	84	91	42	12	12
F209	13	83	—	85	45	12	18
S201	26	72	—	89	36	12	9
Q202	22	77	94	98	77	12	5
S206	52	46	93	96	74	17	49
S212	20	79	95	98	43	12	10
P217	31	68	94	93	39	12	13
G251	22	86	82	87	41	12	17
E207	28	69	73	94	60	12	17
T253	24	77	82	88	55	12	18
L218	13	86	85	94	36	12	15
R255	60	37	79	90	27	12	15
Y254	22	76	94	98	59	12	13
U213	7	92	84	96	43	10	9
D282	23	78	82	95	50	13	16
D212	3	96	44	90	64	14	15
T232	28	70	87	88	34	14	11
D256	12	88	59	74	58	15	15
J233	7	90	81	90	43	14	18
Y292	37	61	96	99	28	12	28
X214	8	90	64	79	49	16	38
C298	26	73	83	63	36	12	57
Mean	24	74	82	90	49	13	19
SD	15	16	13	8	16	2	13

\*Percentage of CD3 $^+$  T cells expressing marker by FACS analysis.

†Total number of days in culture for each T-cell lot.

‡Transduction efficiency as measured by DNA PCR for CD4 $\zeta$ .


approximately 3:1. Similar expansion of T cells from HIV-uninfected donors yields a higher proportion of CD4<sup>+</sup> T cells with a ratio of approximately 1:1 (data not shown). Phenotypic analysis by flow cytometry revealed a high proportion of cells expressing CD62L and CD28, with intermediate expression of CD25. There was no clear association between the proportion of CD4<sup>+</sup> T cells in the final product or transduction efficiency and patterns of in vivo survival of the gene-modified cells.

**Toxicity**

There were no serious adverse events reported, and T-cell infusions overall were associated with minimal toxicity (Table 3). Grade 3 or 4 adverse events were predominantly associated with IL-2 infusion. The most common toxicities of grade 2 or higher seen in the cells-only arm were fever, chills, rash, and sinusitis (each seen in 2 patients). Shift-table analyses of safety laboratory parameters demonstrated an increase in white blood cells and eosinophils in all patients in the cells + IL-2 group and in 8 of 11 in the cells-only group during the first week following infusion. Cholesterol decreased in 20 of 22 patients and lactate dehydrogenase increased in 16 of 17 in both groups combined. All 24 subjects tested negative for RCR by PCR analysis for MLV *env* up to 1 year after infusion.

**CD4 $\zeta$ -modified T-cell survival in peripheral blood**

CD4 $\zeta$ -modified T cells were detected by DNA PCR for the CD4 $\zeta$  gene in the peripheral blood of all patients following infusion. Sustained mean levels of 4.0 to 4.4 log copies/10<sup>6</sup> cells (1% to 3% of PBMCs) were detected at all time points after infusion from day 3 through week 8 in both treatment arms (Figure 2A). Extended follow-up through 12 months in 18 patients demonstrated sustained persistence of CD4 $\zeta$ -modified T cells in the blood of 17 of 18, with mean values of 3.8 log copies (cells + IL-2) and 3.1 log copies (cells only) at 6 months, and 3.1 log copies (cells + IL-2) and 2.9 log copies (cells only) at 12 months. There were no statistically significant differences in survival of gene-modified T cells between the treatment arms. Fractionation of blood T cells was performed in



**Figure 2.** CD4 $\zeta$ -modified T-cell survival and gene expression in peripheral blood mononuclear cells (PBMCs). Gene-modified T-cell infusion was administered at week 0, and patients were followed for at least 8 weeks after infusion. (A) Survival of CD4 $\zeta$ -modified T cells in peripheral blood as measured by quantitative DNA PCR analysis for CD4 $\zeta$  in the cells only ( $\blacktriangle$ ) and cells + IL-2 ( $\blacksquare$ ) treatment cohorts through 8 weeks of follow-up. There were no statistically significant differences between cohorts at any time point after infusion ( $P = .35$ , week 2;  $P = .49$ , week 4;  $P = .93$ , week 8). (B) Immunoselected populations of CD4<sup>+</sup> ( $\blacksquare$ ) and CD8<sup>+</sup> ( $\bullet$ ) T cells in peripheral blood were analyzed for the presence of CD4 $\zeta$  by DNA PCR and compared with the presence of CD4 $\zeta$  in the bulk population ( $\blacktriangle$ ). The results confirmed the persistence of both gene-modified CD4<sup>+</sup> and CD8<sup>+</sup> T cells in 6 of 6 patients analyzed for at least 8 weeks. Results of 1 representative patient (J233) out of a total of 6 analyzed are shown. (C) Persistent, relatively stable expression of the CD4 $\zeta$  gene was confirmed for at least 16 weeks by CD4 $\zeta$  RNA RT-PCR analysis of PBMCs in 6 patients (G251, T253, Y254, Q202, Y292, and J233).

**Table 3. Toxicity**

Adverse events (grades 3, 4)	Cells + IL-2 (n = 11)	Cells only (n = 13)	Total (n = 24)
<b>Clinical*</b>			
Fever	1	0	1
Nausea	1	0	1
Vomiting	1	0	1
Dehydration	1	0	1
Arthralgia	1	0	1
Myalgia	1	0	1
Headache	0	1	1
Dyspnea	1	0	1
Cellulitis	1	0	1
<b>Laboratory</b>			
Phosphate <1.5 mg/dL	1	0	1
AST >165 U/L	0	1	1
GGT >350 U/L	1	0	1
Glucose >250 mg/dL	0	1	1

AST indicates aspartate aminotransferase; GGT, gamma-glutamyl transferase. \*The following grade-2 clinical adverse events were noted in more than 1 patient: fever (6), chills (4), pain (4), myalgia (3), headache (3), rash (3), flu syndrome (2), sinusitis (2), diaphoresis (2), malaise (2), phlebitis (2), anorexia (2), diarrhea (2), nausea (2), and lymphadenopathy (2). Of these, only chills (2), fever (2), rash (2), sinusitis (2), and pain (1) were noted in the cells-only group.

6 patients and demonstrated survival of both gene-modified CD4<sup>+</sup> and CD8<sup>+</sup> T cells in all patients analyzed (Figure 2B). In addition, CD4 $\zeta$  RNA RT-PCR analysis was performed in 6 patients and confirmed relatively stable gene expression for at least 16 weeks (Figure 2C).

### Antiviral activity of CD4 $\zeta$ T cells

Antiviral activity of CD4 $\zeta$  T-cell infusions administered with or without IL-2 was assessed through monitoring of plasma HIV viral load, blood HIV proviral DNA, CD4 $^+$  T-cell counts, and analysis of HIV reservoirs in rectal mucosa. A change in plasma viral load of greater than 0.5 log is unlikely to be explained by inherent biologic or assay variability and is accepted as a clinically relevant change in the level of plasma HIV RNA.<sup>39</sup> There was no change in mean plasma viral load greater than 0.5 log at any time point after infusion in either treatment arm, and differences between arms were not statistically significant (Figure 3A). Two patients (8%; 95% confidence interval [CI], 1% to 27%) experienced a viral load decrease of 0.5 log or greater at week 2. Three patients (23%; 95% CI, 3% to 34%) at week 4, and 1 patient (4%; 95% CI, 0 to 21%) at week 8, suggesting a transient antiviral effect of gene-modified T cells in a subset of patients. There was no statistically significant difference in the proportion of patients experiencing a 0.5 log or greater decrease in viral load between the treatment groups.


The mean change from baseline in blood HIV proviral DNA did not exceed 0.10 log in either treatment arm during the 8-week observation (Figure 3B). However, the HIV proviral DNA assay used in this trial measures total HIV DNA including integrated, unintegrated, and replication-incompetent copies and may not, therefore, accurately reflect changes in replication-competent HIV proviral DNA.

Figure 3C shows the mean change from baseline in the CD4 $^+$  cell counts in the 2 treatment arms. CD4 $^+$  counts decreased transiently in the cells + IL-2 arm during the first 3 days following T-cell infusion (concomitant with IL-2 infusion), which is consistent with transient lymphopenia induced by IL-2 (C. Lane, personal communication). There was an increase in CD4 $^+$  counts in both treatment arms at week 2; however, this increase was sustained only in the cells + IL-2 arm at week 8, with a mean increase of 73 cells/ $\mu$ L (95% CI, 19-127). This is consistent with the expected effect of IL-2 alone.<sup>40</sup> The difference between treatment arms at week 8 was of borderline statistical significance ( $P = .10$ , non-transformed CD4 $^+$  cell count;  $P = .07$ , log-transformed CD4 $^+$  cell count).

### CD4 $\zeta$ T-cell trafficking and activity against gut-associated HIV reservoirs

The gut-associated lymphoid tissue (GALT) serves as an important and accessible tissue reservoir of HIV-infected cells. Five of 6 eligible patients (3 receiving cells only; 2 receiving cells + IL-2) participated in a substudy to investigate the trafficking and antiviral activity of CD4 $\zeta$ -modified T cells against rectal tissue reservoirs of HIV. All 5 completed the planned rectal biopsy procedures (week -1; days 3, 7, and 14), and there were no procedure-related adverse events.

CD4 $\zeta$  signal was measured in PBMCs, bulk tissue, and isolated lamina propria lymphocytes (LPLs) by PCR (Table 4). CD4 $\zeta$  signal was consistently detected in whole biopsy tissue samples in all patients at all time points (mean 2.6 log copies/ $10^6$  tissue cells). The mean CD4 $\zeta$  signal in blood for these 5 subjects over the 14-day observation period was 4.1 log copies/ $10^6$  PBMCs. Long-term follow-up demonstrated persistent CD4 $\zeta$  signal in rectal tissue in 2 of 3 subjects at 1 year. CD4 $\zeta$  signal in the rectal biopsy specimens was consistently lower than that in peripheral blood. This could reflect the difference in the denominator (fractionated lymphocytes versus bulk tissue), the kinetics of trafficking to the gut mucosa, or loss of signal associated with sample processing. All subjects showed an increase in CD4 $\zeta$  signal in bulk rectal tissue from day 3



**Figure 3. Antiviral activity and change in CD4 $^+$  T-cell count following CD4 $\zeta$ -modified T-cell infusion.** Baseline values represent an average of those at week -1 and week 0. T-cell infusion occurred at week 0, and postinfusion analyses were performed on days 1, 2, and 3 and weeks 2, 4, and 8. Scr1 and 2 represent the 2 screening values performed approximately 8 weeks before cell infusion. (A) Mean change from baseline in plasma HIV RNA (Roche Amplicor kit; sensitivity 40 copies/mL). There were no statistically significant differences between the cells only (▲) and cells + IL-2 (■) cohorts at any time point after infusion ( $P = .87$ , week 2;  $P = .70$ , week 4;  $P = .86$ , week 8). (B) Mean change from baseline in blood HIV proviral DNA (DNA PCR for HIV *gag*, Specialty Labs; sensitivity 35 copies/ $10^6$  cells). There were no statistically significant differences between the cells only (▲) and cells + IL-2 (■) cohorts at any time point after infusion ( $P = .84$ , week 2;  $P = .94$ , week 4;  $P = .89$ , week 8). (C) Mean change from baseline in CD4 $^+$  T-cell count. There was a trend toward a greater increase in CD4 $^+$  T-cell counts after infusion in the cells + IL-2 arm (■) compared with the cells-only arm (▲) ( $P = .04$ , week 2;  $P = .14$ , week 4;  $P = .10$ , week 8).

to day 7. Detection of CD4 $\zeta$  in isolated LPLs was less reproducible; however, signal was detected in LPLs from every patient at 1 or more time points after infusion. These data are consistent with the trafficking of gene-modified T cells to rectal lymphoid tissue in all 5 patients with maintenance of CD4 $\zeta$  signal for at least 14 days.

**Table 4. Comparison of rectal tissue and blood HIV RNA and CD4 $\zeta$  persistence**

Patient	Time point, d	HIV RNA		CD4 $\zeta$		
		Tissue (log copies/ $\mu$ g RNA)	Plasma (log copies/mL)	Blood (log copies/ $10^6$ PBMCs)	Bulk tissue (log copies/ $10^6$ cells)	LPLs (log copies/ $10^6$ cells)
S201 (+IL-2)	Preinfusion	4.04	3.13	0	0	0
	3	2.83	3.06	4.23	1.88	0
	7	NA	2.81	4.55	3.04	0
	14	2.90	3.01	4.35	3.15	0.85
	365	NA	NA	NA	NA	NA
Q202 (-IL-2)	Preinfusion	2.16	4.14	0	0	0
	3	2.14	NA	4.37	1.38	1.67
	7	2.24	4.60	NA	2.41	1.62
	14	1.63	4.03	4.07	1.85	0
	365	NA	NA	3.08	0	NA
E207 (-IL-2)	Preinfusion	2.62	4.42	0	0	3.36
	3	2.15	4.68	4.28	2.84	2.08
	7	2.57	4.65	NA	2.91	2.36
	14	2.09	5.24	3.20	2.94	2.77
	365	NA	NA	3.42	2.44	NA
U213 (+IL-2)	Preinfusion	2.72	5.10	0	0	0
	3	3.13	5.08	4.26	2.63	0
	7	2.87	4.23	4.03	3.55	2.18
	14	2.20	4.79	3.59	1.68	0
	365	NA	NA	NA	NA	NA
D212 (-IL-2)	Preinfusion	3.52	4.61	0	0	0
	3	2.56	4.98	4.16	2.60	3.20
	7	2.26	4.92	NA	2.78	2.47
	14	3.51	4.84	3.78	2.86	3.41
	365	NA	NA	2.88	2.24	NA
Mean	Preinfusion	3.10	4.33	0	0	0.67
	3	2.60	4.45	4.26	2.27	1.39
	7	2.48	4.24	4.29	2.94	1.73
	14	2.47	4.38	3.80	2.50	1.41
Composite mean (days 3-14)		2.52	4.36	4.10	2.60	1.30

PBMCs indicates peripheral blood mononuclear cells; LPLs, lamina propria lymphocytes; NA, data not available; IL-2, interleukin 2.

Rectal tissue-associated HIV RNA load was measured by HIV RNA RT-PCR analysis (Table 4). The mean tissue viral load decreased from the preinfusion value by at least 0.5 log copies/ $\mu$ g RNA at all time points after infusion. Four of 5 patients showed a 0.5 log or greater decrease at 2 of 3 time points, and 2 of 5 showed a 0.5 log or greater decrease at all measured time points. Three patients had a 1.0 log or greater decrease in tissue HIV RNA at 1 or more time points after infusion. These preliminary data suggest antiviral activity of CD4 $\zeta$ -modified T cells against gut-associated reservoirs of HIV. There were too few patients to assess the impact of concomitant IL-2 administration; however, both tissue trafficking and antiviral activity were demonstrated in patients in both treatment arms. The duration of this effect and verification of these results will require further study.

Measurement of plasma-associated HIV RNA did not follow the same trend as seen in HIV RNA in the gut tissue in these 5 patients (Table 4). There was no significant mean change ( $> 0.5$  log copies/mL) in plasma viral load during the 14-day observation period; however, 1 of 5 patients showed an isolated decrease in plasma viral load of at least 0.5 log at day 7.

## Discussion

We have developed a rapid T-cell manufacturing process that reliably yields 2 to 3  $\times 10^{10}$  gene-modified T cells within 2 weeks. This process was successful in 24 of 25 enrolled patients and yielded a mixed population of CD4 $^+$  and CD8 $^+$  T cells with an

activated cell phenotype (high expression of CD28, CD25, and CD62L). Bulk transduction efficiency in this trial was approximately 20% and, with further processing improvements, has been increased to 40%.<sup>41</sup> This high-level transduction eliminates the need for posttransduction purification of gene-modified cells, allowing for the brief period of ex vivo expansion.

CD4 $\zeta$ -modified CD4 $^+$  and CD8 $^+$  T cells persisted in the blood of all patients at high levels (1% to 3% of PBMCs) throughout the 8-week observation period, and extended follow-up demonstrated maintained survival for at least 1 year in 17 of 18 subjects (0.1% of PBMCs). This long-term persistence is in marked contrast to our previous experience with infusion of syngeneic CD4 $\zeta$ -modified CD8 $^+$  T cells in HIV-infected twin pairs as well as the previously published experience with adoptive T-cell therapy in HIV infection reported by other groups. In the syngeneic twin study, gene-modified CD8 $^+$  T cells were purified and expanded in IL-2 for a mean of 62 days. Peak circulating levels of CD4 $\zeta$ -modified T cells of 1% to 10% of PBMCs were observed at 48 hours, followed by a 2- to 3-log decrease within 8 weeks of adoptive transfer (manuscript submitted). Infusion of autologous *neo*-marked HIV *gag*-specific CD8 $^+$  T cells by another group showed similarly poor survival patterns, with *neo*-marked cells constituting 2% to 3.5% of CD8 $^+$  T cells in blood 1 day after infusion ( $3.3 \times 10^9$  cells/ $m^2$ ), and with a rapid decline to fewer than 5 cells per  $10^6$  PBMCs by 3 weeks.<sup>24</sup> The most likely explanation for the improved T-cell survival, independent of exogenous IL-2, seen in this trial is a helper effect conferred by CD4 $\zeta$ -modified CD4 $^+$  T cells. However,



changes in ex vivo T-cell stimulation and/or the shorter total duration of ex vivo cell culture (mean of 13 versus 62 days) may also have played a role. This high-level, sustained, IL-2-independent survival of gene-modified autologous T cells validates this approach as a platform technology for gene delivery.

The T-cell culture method used in this study provided costimulation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells by antibodies to CD3 and CD28 co-immobilized on magnetic beads. This differs from the original twin study in which single signal T-cell stimulation of purified CD8<sup>+</sup> T cells with anti-CD3 and high-dose IL-2 was employed. This new cell culture method allows ex vivo proliferation of CD4<sup>+</sup> T cells and renders CD4<sup>+</sup> T cells resistant to infection with M-tropic strains of HIV through down-regulation of the HIV fusion coreceptor CCR5.<sup>31,42</sup> In preclinical experiments at Cell Genesys, this method generated T cells that were resistant to antigen-induced apoptosis, whereas CD3/IL-2-stimulated cells died rapidly following repeated rounds of stimulation through the CD4 $\zeta$  receptor. Furthermore, this new process generated CD4<sup>+</sup> T cells capable of proliferation and IL-2 secretion upon CD4 $\zeta$  receptor engagement. Gene-modified CD4<sup>+</sup> and CD8<sup>+</sup> T cells showed equivalent cytolytic activity against HIV *env*-bearing targets and equivalent potency in suppression of HIV replication in infected T-cell cultures as CD8<sup>+</sup> T cells alone cultured using anti-CD3/IL-2.<sup>43</sup> The markedly improved, sustained, high-level in vivo survival of both gene-modified CD4<sup>+</sup> and CD8<sup>+</sup> T cells in this trial is consistent with these preclinical observations and suggests that mixed CD4<sup>+</sup> and CD8<sup>+</sup> T-cell populations provide HIV-specific T-helper function.

Preliminary evidence of antiviral activity of CD4 $\zeta$ -modified CD4<sup>+</sup> and CD8<sup>+</sup> T cells was observed in this trial. Although there was no significant mean change, several patients experienced a plasma viral load decrease of greater than 0.5 log on at least 1 occasion, suggesting a transient antiviral effect in a subset of patients. Furthermore, a greater than 0.5 log mean decrease in rectal mucosa-associated HIV RNA was detected from days 3 through 14 in a subset of 5 patients who underwent serial rectal biopsies, suggesting antiviral activity against this important tissue reservoir of HIV. This antiviral effect correlated with detection of CD4 $\zeta$ -modified T cells in the rectal tissue of all 5 patients throughout the 14-day monitoring period, with increasing signal from day 3 to day 7. Possible explanations for the discordance between changes in gut and plasma viral loads include true compartment differences in the activity of gene-modified T cells, differences in the kinetics of activity between the compartments, or insufficient magnitude of effect in the gut compartment to be

reflected in plasma viral load. Expression of the  $\beta$ 7 integrin subfamily of adhesion molecules has been shown to be critically important for lymphocyte trafficking to GALT, and the formation of GALT is severely impaired in mice deficient for this receptor family.<sup>44</sup> Subsequent experiments have confirmed the expression of  $\alpha$ 4 $\beta$ 7 on CD4 $\zeta$ -modified T cells at the end of ex vivo cell culture (unpublished data). The gastrointestinal tract contains most of the lymphoid tissue in the body and has been shown to be a major target for SIV replication and CD4<sup>+</sup> T-cell loss in early SIV replication following intravenous inoculation in Rhesus macaques.<sup>45</sup> Therefore, demonstration of antiviral activity against this tissue reservoir of HIV is likely to be important in the evaluation of novel agents. We did not investigate lymph node trafficking of CD4 $\zeta$ -modified T cells in this study; however, another group has demonstrated accumulation of *neo*-marked HIV-specific CD8<sup>+</sup> T cells adjacent to infected CD4<sup>+</sup> T cells in lymph nodes, confirming the ability of adoptively transferred lymphocytes to migrate to this lymphoid reservoir.<sup>24</sup>

The results of this clinical trial validate the feasibility of adoptive immunotherapy of HIV infection with genetically modified, MHC-unrestricted, polyclonal T cells bearing chimeric HIV *env*-specific immune receptors and provide preliminary evidence of tissue homing and antiviral activity against tissue reservoirs of HIV. Our belief, based on the experience in adoptive T-cell immunotherapy of cancer, is that this therapy is most likely to demonstrate convincing clinical efficacy in subjects with minimal viral burden. Among patients receiving donor lymphocyte infusions for relapsed chronic myelogenous leukemia following bone marrow transplantation, remissions are most frequent in patients with cytogenetic or early hematologic relapse and less common in patients with advanced disease.<sup>46</sup> We have therefore initiated a randomized controlled clinical trial of CD4 $\zeta$ -modified versus -unmodified T cells in 40 HIV-infected subjects with undetectable plasma viral loads taking combination antiretroviral therapy to measure the efficacy of this gene therapy against residual blood and tissue reservoirs of HIV.

## Acknowledgments

We would like to acknowledge the following people for their contributions to this study: Judith Carden, Alison Leiblein, Julie Elliott, Dorie Heeren, Walter Howard, Kathleen Shea, Virginia Waite, Janet Wittes, Lynne Fitch, and David Broad.

## References

- Musey L, Hughes J, Schacker T, et al. Cytotoxic T cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. *N Engl J Med*. 1997;337:1267-1274.
- Greenough T, Brettler D, Somasundaran M, Panicali D, Sullivan J. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. *J Infect Dis*. 1997;176:118-125.
- Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1) specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. *J Exp Med*. 1993;177:249-256.
- Klein M, Van Baalan C, Holwerda A, et al. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. *J Exp Med*. 1995; 181:1365-1372.
- Rinaldo C, Huang XL, Fan ZF, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. *J Virol*. 1995;69:5838-5842.
- Pinto LA, Sullivan J, Berzofsky JA, et al. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. *J Clin Invest*. 1995;96:867-876.
- Furci L, Scarlatti G, Burastero S, et al. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 alleles. *J Exp Med*. 1997;186:455-460.
- Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8<sup>+</sup> lymphocytes. *Science*. 1999;283:857-860.
- Jin X, Bauer D, Tuttleton S, et al. Dramatic rise in plasma viremia after CD8<sup>+</sup> T cell depletion in simian immunodeficiency virus-infected macaques. *J Exp Med*. 1999;189:991-998.
- Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. *N Engl J Med*. 1995;333:1038-1044.
- Riddell S, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. *Science*. 1992;257:238-241.

12. Valentine F, Palino A, Saito A, Holzman R. Lymphocyte-proliferative responses to HIV antigens as a potential measure of immunological reconstitution in HIV disease. *AIDS Res Hum Retroviruses*. 1998;14:S161-S166.
13. Rosenberg E, Walker B. HIV type 1-specific helper T cells: a critical host defense. *AIDS Res Hum Retroviruses*. 1998;14:S143-S147.
14. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. *Science*. 1997;278:1447-1450.
15. Pitcher C, Quittner C, Peterson D, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. *Nat Med*. 1999;5:518-525.
16. Riddell SR, Greenberg PD, Overell RW, et al. Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. *Hum Gene Ther*. 1992;3:319-338.
17. Heslop HE, Ng CYC, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. *Nat Med*. 1996;2:551-555.
18. Rooney CM, Smith CAC, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. *Lancet*. 1995;345:9-13.
19. Rooney C, Smith C, Ng C, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. *Blood*. 1998;92:1549-1555.
20. Greenberg PD, Finch RJ, Gavin MA, et al. Genetic modification of T-cell clones for therapy of human viral and malignant diseases. *Cancer J Sci Am*. 1998;4:S100-S105.
21. Riddell SR, Elliott M, Lewinsohn DA, et al. T cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. *Nat Med*. 1996;2:216-223.
22. Koenig S, Conley AJ, Brewah YA, et al. Transfer of HIV-1 specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. *Nat Med*. 1995;1:330-336.
23. Lieberman J, Skolnik P, Parkerson G, et al. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. *Blood*. 1997;90:2196-2206.
24. Brodie S, Lewinsohn D, Patterson B, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. *Nat Med*. 1999;5:34-41.
25. Roberts MR, Qin L, Zhang D, et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. *Blood*. 1994;84:2878-2889.
26. Howcroft TK, Strebel K, Martin MA, Singer DS. Repression of MHC class I gene promoter activity by two-exon Tat of HIV. *Science*. 1993;260:1320-1322.
27. Schwartz O, Marechal V, LeGall S, Lemonnier F, Heard J-M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. *Nat Med*. 1996;2:338-342.
28. Kerkau T, Bacik I, Bennink J. The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. *J Exp Med*. 1997;185:1295-1305.
29. Yang OO, Tran AC, Kalams SA, et al. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. *Proc Natl Acad Sci U S A*. 1997;94:11478-11483.
30. Walker R, Bechtel C, Natarajan V, et al. In vivo persistence of genetically modified HIV-1-specific syngeneic lymphocytes in HIV-1-discordant identical twins. Paper presented at: 12th World AIDS Conference; Geneva, Switzerland, 1998, 838.
31. Levine BL, Mosca J, Riley J, et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. *Science*. 1996;272:1939-1943.
32. Finer MH, Dull TJ, Qin L, Farson D, Roberts MR. *kat*: a high-efficiency retroviral transduction system for primary human T lymphocytes. *Blood*. 1994;83:43-50.
33. Lander MR, Chattopadhyay SK. A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ecotropic, amphotropic, xenotropic and mink cell focus-forming viruses. *J Virol*. 1984;52:695-698.
34. Hahn B, Shaw G, Arya S, et al. Molecular cloning and characterization of the HTLV-III virus associated with AIDS. *Nature*. 1984;312:166-169.
35. Anton P, Elliott J, Poles M, et al. Increased expression of chemokine receptors on mucosal ver-
36. Anton PA, Elliott J, Poles M, et al. Quantitative assessment of tissue viral burden using a single intestinal biopsy. Paper presented at: International Workshop on HIV Drug Resistance & Treatment Strategies; June 21-27, 1998; Lake Maggiore, Italy.
37. Poles M, Elliott J, Brown S, et al. HIV-1 is detectable in mucosal biopsies from patients with undetectable plasma viral loads. Paper presented at: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL.
38. Zack JA, Arrigo SJ, Weitsman SR, et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. *Cell*. 1990;61:213-222.
39. Feinberg MB, Carpenter C, Fauci AS, et al. Report of the NIH panel to define principles of therapy of HIV infection. *Ann Intern Med*. 1998;128:1057-1079.
40. Kovacs J, Vogel S, Albert J, et al. Controlled trial of interleukin-2 in patients infected with the human immunodeficiency virus. *N Engl J Med*. 1996;335:1350-1356.
41. Warren R, Fisher G, Bergsland E, et al. Clinical studies of regional and systemic gene therapy with autologous CC49- $\zeta$  modified T cells in colorectal cancer metastatic to the liver. *Cancer Gene Ther*. 1998; 5:51.
42. Carroll RG, Riley JL, Levine BL, et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. *Science*. 1997;276:273-276.
43. Hege K, Walker R, Lane C, Roberts M, Broad D. Cell processing improvements and co-transduction of CD4 and CD8 T cells for HIV gene therapy. Paper presented at: Fifth Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, IL.
44. Wagner N, Lohler J, Kunkel E, et al. Critical role for  $\beta$ 7 integrins in formation of the gut-associated lymphoid tissue. *Nature*. 1996;382:366-370.
45. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. *Science*. 1998;280:427-431.
46. Kolb J-J, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. *Blood*. 1995;5:2041-2050.